Current version snapshot
Current · version 3: Maridebart cafraglutide↗
Related names recorded in this version: MariTide, AMG 133↗
An experimental Amgen antibody-peptide conjugate, also called MariTide, that blocks the GIP receptor and activates the GLP-1 receptor. It is in Phase 3 trials and not FDA-approved.↗↗↗
The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, Phase 2 results from our human evidence review, and retained ClinicalTrials.gov records for Phase 3 trials. 234
What this version reported
A large 52-week randomized Phase 2 trial reported weight loss compared with placebo in people with obesity, with common gastrointestinal side effects. Phase 3 trials, including a cardiovascular outcomes trial, are registered.↗↗↗
- Amgen↗
Trial records: NCT07717814
Reader guide in this version
Key takeaway
Maridebart cafraglutide, also called MariTide or AMG 133, is an experimental Amgen drug that joins an antibody to GLP-1-like peptides: it blocks the GIP receptor and activates the GLP-1 receptor.1,2 It is not FDA-approved. Amgen is running Phase 3 trials, and none of the sources reviewed here reports an approval in any country.3,4 In a 52-week randomized Phase 2 trial of 592 people with obesity, average weight change ranged from −12.3% to −16.2% without diabetes, compared with −2.5% on placebo. Gastrointestinal side effects were common.2
At a glance
- What it is
- An investigational antibody-peptide conjugate from Amgen that combines GIP-receptor blocking with GLP-1-receptor activation.1,2
- FDA status
- Not FDA-approved. Amgen has registered Phase 3 trials on ClinicalTrials.gov, including MARITIME-1 and MARITIME-CV.3,4
- Human evidence
- A large 52-week randomized, placebo-controlled Phase 2 trial in people with obesity, with or without type 2 diabetes. Phase 3 trials are registered.2,3
- Evidence strength
- Large randomized human trials
What is maridebart cafraglutide?
Maridebart cafraglutide is an experimental drug from Amgen, which ClinicalTrials.gov lists as the sponsor of its trials. It is also known as MariTide and by its development code, AMG 133.1,3
The published Phase 2 report describes it as an antibody-peptide conjugate: an antibody that blocks the GIP receptor, linked to peptides that activate the GLP-1 receptor.2
How is maridebart cafraglutide thought to work?
The drug combines two actions on gut-hormone receptors involved in appetite and blood sugar: it blocks the receptor for GIP and activates the receptor for GLP-1.2
The sources reviewed here do not establish how much each action contributes to the effects reported in trials.2
What do human studies show?
In a 52-week randomized, placebo-controlled Phase 2 trial, 592 people with obesity were assigned to several maridebart cafraglutide groups or placebo. Among the 465 without diabetes, average weight change ranged from −12.3% to −16.2%, compared with −2.5% on placebo.2
Among the 127 with type 2 diabetes, average weight change ranged from −8.4% to −12.3%, compared with −1.7% on placebo. Gastrointestinal events were common.2
Weight change over 52 weeks does not show effects on heart attacks, strokes or other long-term outcomes, which the MARITIME-CV trial is registered to study.2,4
What the evidence base contains
- Large randomized human trial A 52-week randomized, placebo-controlled Phase 2 trial (NCT05669599) in 592 participants with obesity, 465 without diabetes and 127 with type 2 diabetes, published in The New England Journal of Medicine.2
- Registered trial without results MARITIME-1 (NCT06858839), a Phase 3 trial in obesity listed as active, not recruiting in its September 17, 2026 registry record, and MARITIME-CV (NCT07037433), a Phase 3 cardiovascular outcomes trial listed as recruiting in its July 24, 2026 record.3,4
- Registered trial without results A Phase 3 trial in heart failure with obesity (NCT07037459) and a Phase 2 trial in type 2 diabetes (NCT06660173), registered on ClinicalTrials.gov.5,6
Evidence-strength label: Large randomized human trials. How this label is assigned
Is maridebart cafraglutide FDA-approved?
No. Maridebart cafraglutide remains in clinical trials. None of the sources reviewed here reports an approval of maridebart cafraglutide in any country.2,3,4
As of their retained registry records, MARITIME-1, a Phase 3 obesity trial, was listed as active, not recruiting on September 17, 2026, and MARITIME-CV, a Phase 3 cardiovascular outcomes trial, as recruiting on July 24, 2026.3,4
Amgen has also registered a Phase 3 trial in heart failure with obesity and a Phase 2 trial in type 2 diabetes.5,6
What is still unknown?
What the Phase 3 trials will show: their results are not part of the sources cited here.3,4
Its long-term safety and effects on cardiovascular outcomes, which the Phase 2 trial did not measure.2
Sources for this version
- 1Bioavailability of AMG 133 in Participants With Overweight or Obesity · record history version 1 · last update posted 2026-07-21 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 2Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial (2025) · PMID 40549887 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026
- 3ClinicalTrials.gov record NCT06858839 · retained source version 2026-09-17:beb2c75eb0a3bc43ffe1b4c9fab269e89fcf8ae6cbe11f7d4c3ea4213aed3e04 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026
- 4ClinicalTrials.gov record NCT07037433 · retained source version 2026-07-24:ae9704758762002a715a9ed9f57da8845f1a2ea224c8296b8200071653366d78 ↗
ClinicalTrials.gov · Official source · Source checked August 13, 2026
- 5ClinicalTrials.gov record NCT07037459 · retained source version 2026-07-02:199638062a19e7df645ce1f76202d15ba272ee303ca7769667116afd6858e958 ↗
ClinicalTrials.gov · Official source · Source checked August 13, 2026
- 6ClinicalTrials.gov record NCT06660173 · retained source version 2026-09-11:dfcf2dd8720eee75605fef185ae1153439869797ef1a2e2f6d827aef846b701b ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026